Semaglutide

Name: Semaglutide
Brand: Peak Research Peptides
SKU: PRP-SEMAGLUTID
Price: 85.00 USD
Availability: OutOfStock

GLP-1 receptor research peptide supplied for in-vitro receptor-binding assays.

Receptors & targets

GLP-1R

Sequence / structure

31-amino-acid GLP-1 receptor peptide with C18 fatty-diacid moiety.

Handling

Storage: Store lyophilized at −20 °C. Protect from light.

Verified before release

Every lot of Semaglutide is analysed against the specification below before any vial is released.

≥0.00%purity by HPLC · specification ≥ 95%

Parameter	Result	Method	Specification
Appearance	White lyophilised powder	Visual	White lyophilised powder
Purity	≥ 99.00%	HPLC	≥ 95%
Identity	Confirmed	HPLC / MS	Meets specification
Heavy metals	Not detected	ICP-MS	Pass
Sterility	No growth	PCR	Pass
Endotoxin	Within limit	USP <85>	Report

Analysis is carried out on every lot before release. If you are supplying material onward, run your own confirmatory testing on arrival — our work supports yours, it does not replace it.

Specification

Presentation: 5 mg / vial
Molecular formula: C187H291N45O59
Molecular weight: 4113.6 g/mol
CAS: 910463-68-2
Grade: Research use only (RUO)

$85.00

Dosage

5 mg / vial — sold out

For laboratory and research purposes only. Not for human or animal consumption.

Published literature

Peer-reviewed research on Semaglutide, indexed in PubMed. Listed so you can read the primary sources directly.

Nat Med
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Apperloo EM, Gorriz JL, Soler MJ et al.
2025PMID 39455729DOI
N Engl J Med
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C et al.
2025PMID 40544432DOI
NEJM Evid
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah VN, Akturk HK, Kruger D et al.
2025PMID 40550013DOI
N Engl J Med
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod MN, Petrie MC, Borlaug BA et al.
2024PMID 38587233DOI
Trends Cardiovasc Med
Semaglutide for the treatment of obesity
Chao AM, Tronieri JS, Amaro A et al.
2023PMID 34942372DOI
N Engl J Med
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM et al.
2023PMID 37952131DOI

These papers are the published research on this molecule. They are not a claim about this product, and nothing here describes an intended use. All material is supplied for laboratory research only.